Global Pharma and Biotech Clinical Stage Partnering Terms and Agreements 2014-2020: Access to Headline, Upfront, Milestone and Royalty Data


Dublin, Sept. 14, 2020 (GLOBE NEWSWIRE) -- The "Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020" report has been added to ResearchAndMarkets.com's offering.

The Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2020 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 2,300 clinical stage partnering deals announced since 2014 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.

The report also includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2014.

Key benefits

  • In-depth understanding of clinical stage deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of clinical stage agreements with numerous real life case studies
  • Insight into the terms included in a clinical stage agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2020 includes:

  • Trends in clinical stage dealmaking in the biopharma industry since 2014
  • Analysis of clinical stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life clinical stage deals
  • Access to over 2,300 clinical stage deals
  • The leading clinical stage deals by value since 2014
  • Most active clinical stage dealmakers since 2014
  • The leading clinical stage partnering resources

In Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014- 2020, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

For more information about this report visit https://www.researchandmarkets.com/r/sw6a15

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

 

Contact Data